Philosophical Psychology
July 25, 2024
Umair Khan
1 citation
ABSTRACT Psychedelics have shown promise as a treatment for depression. Although there is some debate, a popular view is that psychedelics produce their benefits in an experience-dependent manner. This is the view that a depressed person gets better, inter alia, because of the experience she has had on psychedelics. Among the various questions that treatment for depression with psychedelics...
Studies in health technology and informatics
July 24, 2024
Tso-Ying Lee, Cha-Jung Hsieh, Pi-Hsia Lee
COVID-19 epidemic bring a great threat to human physical and mental health. This study aimed to investigate the effectiveness of an online mindfulness platform in improving mental status. Patients from a regional hospital were randomly divided into the experimental and control groups. The experimental group received online mindfulness interventions, and control group received general health...
BMC Psychiatry
July 18, 2024
Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al.
11 citations
Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management...
Frontiers in Psychiatry
July 16, 2024
André Do, Vanessa Michaud, Jean-François Stephan et al.
3 citations
Psilocybin has reemerged as a promising treatment for difficult-to-treat depression (DTD). Although there is limited evidence regarding interactions between psilocybin and other psychotropic drugs, clinical trials require that patients discontinue their antidepressants before study entry to isolate the benefits of psilocybin and to minimize the risk of adverse events. We present the first case...
Journal of Affective Disorders
July 15, 2024
Kelly T Hurst, Abigail Vogeley, Deanna K Greenstein et al.
8 citations
Participants who received ketamine at the NIMH were among the first to receive ketamine for depression in controlled clinical trials, providing a unique opportunity to assess long-term outcomes. This analysis evaluated the relationship between participating in a ketamine clinical trial and subsequent ketamine/esketamine use after leaving the research setting. Participants seen within the NIMH...
European Archives of Psychiatry and Clinical Neuroscience
July 13, 2024
Jenessa N Johnston, Carlos A. Zarate, Mark D Kvarta
18 citations
The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant depression (TRD) are significant advances in the development of novel neuropsychiatric therapeutics. Esketamine is now recognized as a powerful tool for addressing persistent symptoms of TRD compared to traditional oral...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
July 11, 2024
Eva M. Geoghegan
Introduction: Ketamine has been shown to have rapid antidepressant effects. In addition, the use of EEG in depression offers a new approach to diagnose patients. It is necessary to understand locational-based EEG and MEG changes following ketamine in patients with depression to establish a potential biomarker panel. This study sought to identify consistent changes in band power as well as to...
Journal of Anesthesia and Translational Medicine
July 11, 2024
Kenji Hashimoto, Mingming Zhao, Tingting Zhu et al.
32 citations
Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, is similarly employed for anesthesia and analgesia. The anesthetic effects of both ketamine and esketamine arise from their antagonism of the N-methyl-D-aspartate receptor (NMDAR). In field of psychiatry, the rapid-acting antidepressant properties of ketamine for...
Journal of Psychedelic Studies
July 11, 2024
Alyssa B. Oliva, Mitch Earleywine, Fiona Low et al.
AbstractBackground and AimsResearch on psychedelic-assisted therapy (PAT), a promising treatment option for major depression, has not revealed if potential clients show preferences about the demographic characteristics of providers comparable to those common in other forms of psychotherapy. Previous work suggests that honoring comparable client preferences can enhance therapeutic outcomes. This...
Quality in Sport
July 10, 2024
Patrycja Brzozowska, Klaudia Bulska, Konrad Sławek et al.
In spite of the variety of antidepressant drugs available for treating depressive disorder, treatment resistant depression (TRD) is still prevalent among the population. Despite being used mainly in anesthesia, and mostly phased out by more modern anesthetics, ketamine shows potential when it comes to depressive disorder treatment. We've set out to investigate the the relevant body of work to...
Vertex Revista Argentina de Psiquiatría
July 10, 2024
Mariana Zarankin, María S Pellegrini, Francisco Zenteno
2 citations
Major depression disorder is an entity with high prevalence and worldwide impact. Current treatments present a non-response rate of 15-30%, and certain adverse effects are seen like apathy syndrome and lack of emotional response. It is stated that the treatment with psilocybin fungi allows the possibility of dose reduction and suspension of classic psychotropic drugs and entails changes on an...
BMJ
July 8, 2024
Cecilia Njenga, Parashar Pravin Ramanuj, Frederico José Coelho de Magalhães et al.
44 citations
Major depressive disorder (MDD) affects a substantial portion of the population; however, much is still unknown about the pathophysiology of this disorder. Treatment resistance highlights the heterogeneous nature of MDD and the need for treatments to target more than monoamine neurotransmission. This review summarizes research into the new and emerging targets of MDD. These include drugs such...
Psychopharmacology
July 4, 2024
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz et al.
18 citations
Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (TRD). Focusing on Wistar-Kyoto (WKY) rats with a TRD phenotype and Wistar (WIS) rats as a normative comparison, we investigated behavioral and neuroplasticity-related responses to PSI, striving to shed light on the distinctive features of its...
ACS Chemical Neuroscience
July 3, 2024
Yue Zhang, Hui Ma, Yafan Bai et al.
25 citations
Chronic neuropathic pain and comorbid depression syndrome (CDS) is a major worldwide health problem that affects the quality of life of patients and imposes a tremendous socioeconomic burden. More than half of patients with chronic neuropathic pain also suffer from moderate or severe depression. Due to the complex pathogenesis of CDS, there are no effective therapeutic drugs available. The lack...
Trials
July 3, 2024
Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt et al.
3 citations
Major depressive disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin may be a safe and...
Indian Journal of Psychiatric Nursing
July 1, 2024
V. Ramasubramanian, S. Mathumathi, G. Thirumalaisamy et al.
ABSTRACT Depression is a common illness that affects about 3.8% of the population worldwide. Patients with major depression respond to antidepressant treatment, but 10%–20% of them do not improve or show a partial response. It is coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. Treatment-resistant...
Mindfulness
July 1, 2024
Jelle Lubbers, Philip Spinhoven, Mira B. Cladder-Micus et al.
Abstract Objectives Mindfulness-Based Cognitive Therapy (MBCT) reduces recurrence and current depressive symptoms in patients with major depressive disorder (MDD). To understand how and for whom MBCT works, a person-centered approach focusing on mindfulness profiles can be useful. Four mindfulness profiles, each associated differently with mental health outcomes, have previously been...
Neuropharmacology
July 1, 2024
Kevin T Krupp, Jazmine D W Yaeger, Leighton J Ledesma et al.
11 citations
Psychedelic compounds have potentially rapid, long-lasting anxiolytic, antidepressive and anti-inflammatory effects. We investigated whether the psychedelic compound (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI], a selective 5-HT2A receptor partial agonist, decreases stress-related behavior in male mice exposed to repeated social aggression. Additionally, we explored the likelihood that these...
Cureus
July 1, 2024
Cristian I Babos, Giovanni Zucchi, Augusto E Filimberti et al.
1 citation
Introduction Our study aimed to compare meditation and compassion-based group therapy with the standard of care in patients with eating disorders, drug addiction, alcohol addiction, and depression, concerning acceptance, mindfulness awareness, self-compassion, and psychological distress. Methods A controlled designed study was performed, comparing meditation and compassion-focused group therapy...
Journal of pharmacy & bioallied sciences
July 1, 2024
Jayalakshmi Lakshmanan, Bhuvaneswari Gopalakrishnan, Shankar Shanmugam Rajendran
1 citation
The global demographic shift toward an older population is witnessing an increase in age-related psychological disorders and chronic illnesses, particularly among those residing in old age homes. Mind-body interventions (MBIs) have shown promise in enhancing mental and physical health without the adverse effects associated with pharmaceuticals. This quasi-experimental study involved 42 elderly...